You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR EFFEXOR XR


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for EFFEXOR XR

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT05875610 ↗ Preventive Approach Using Venlafaxine Recruiting Mit Ghamr Oncology Center Phase 4 2023-05-01 Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for EFFEXOR XR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001483 ↗ Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression Completed National Institute of Mental Health (NIMH) Phase 2 1995-06-01 This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
NCT00043550 ↗ Treatments for Depression: Drug Versus Psychotherapy Completed National Institute of Mental Health (NIMH) Phase 3 2001-11-01 This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
NCT00043550 ↗ Treatments for Depression: Drug Versus Psychotherapy Completed University of Pennsylvania Phase 3 2001-11-01 This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.
NCT00045916 ↗ Optimizing Electroconvulsive Therapy for Depression Completed National Institute of Mental Health (NIMH) Phase 4 2001-02-01 This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.
NCT00045916 ↗ Optimizing Electroconvulsive Therapy for Depression Completed New York State Psychiatric Institute Phase 4 2001-02-01 This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT.
NCT00046020 ↗ Study Evaluating Venlafaxine ER in Recurrent Depression Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2000-08-01 The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EFFEXOR XR

Condition Name

Condition Name for EFFEXOR XR
Intervention Trials
Depression 15
Healthy 12
Major Depressive Disorder 10
Depressive Disorder, Major 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EFFEXOR XR
Intervention Trials
Depression 33
Depressive Disorder 28
Depressive Disorder, Major 15
Disease 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EFFEXOR XR

Trials by Country

Trials by Country for EFFEXOR XR
Location Trials
United States 115
Japan 47
Canada 12
China 12
Australia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for EFFEXOR XR
Location Trials
New York 10
Florida 8
California 6
North Carolina 6
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EFFEXOR XR

Clinical Trial Phase

Clinical Trial Phase for EFFEXOR XR
Clinical Trial Phase Trials
Phase 4 23
Phase 3 9
Phase 2 6
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EFFEXOR XR
Clinical Trial Phase Trials
Completed 48
Withdrawn 4
Unknown status 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EFFEXOR XR

Sponsor Name

Sponsor Name for EFFEXOR XR
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 7
Teva Pharmaceuticals USA 5
National Institute of Mental Health (NIMH) 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EFFEXOR XR
Sponsor Trials
Other 52
Industry 32
NIH 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.